Progenics Pharma (PGNX) Reports Complete Enrollment in Pivotal Phase 3 CONDOR Study of PyL for the Detection of Prostate Cancer

August 5, 2019 8:37 AM
Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) today announced that it has completed enrollment five months ahead of schedule in the Company’s ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles